News

Video courtesy of Eyewire | TV

STAMFORD, Conn., Oct. 10, 2019 /PRNewswire/ —  TECLens, a medical device manufacturer, today announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens® ‘on-eye’ cross-linking system for corneal remodeling.   Clinical trial results are anticipated in early 2020.

TECLens’ proven CXLens® will provide patients with a comfortable, non-invasive alternative to the treatment of ectatic disorders.   Unlike any other cross-linking system, CXLens® does not require an eyelid speculum.  The patient can relax during the therapy, with his or her eyes open or closed.  The CXLens® tracks precisely with the patient’s eye and head movement, so there are no targeting errors and no need for a technician to monitor the beam position during treatment. 

Dr. Juan Batlle, the Principle Investigator on the study commented, “The CXLens device is easy to use and is well tolerated by my patients. For the first time I have been able to perform corneal collagen cross-linking with minimal to no discomfort following the procedure, and yet have been able to see significant improvement in both visual and refractive outcomes while stabilizing patients’ corneal ectasia.”

“We are very happy with how the system performed in Dr. Batlle’s hands.  The TECLens platform should significantly increase clinical efficiency and procedure margin for physicians practicing corneal cross-linking, while providing a much more patient friendly procedure for patients.”, said TECLens CEO, David Acker.

About TECLens

Based in Stamford, CT, TECLens is a clinical-stage medical device company developing an innovative, non-invasive cornea cross-linking procedure to treat keratoconus, low order myopia and eventually presbyopia.  TECLens’ proprietary ‘on-eye’ CXL technology consists of a single-use disposable contact lens (CXLens®) and a small control system.  The system can treat both eyes simultaneously for keratoconus, and provides integrated real-time ultrasound feedback and patterned ultraviolet light delivery for refractive indications.  TECLens believes on-eye cross-linking will become a safe, simple, and permanent alternative to LASIK, contact lenses, and eyeglasses for millions of people with vision errors.

STAMFORD, Conn., Oct. 7, 2019 /PRNewswire/– TECLens, a medical device manufacturer and SERVimed Industrial Spa, an ophthalmic medical devices manufacturer and distributor today announced their partnership aimed at development and FDA approval of a new combination product to treat keratoconus. The new product under development will combine TECLens’ CXLens® ‘on-eye’ cross-linking system for corneal remodeling with SERVImed’s trans-epithelial RIBOCROSS riboflavin drug formulation.

TECLens and SERVImed will pursue FDA approval for the combination product of CXLens® / RIBOCROSS to treat keratoconus that affects more than a million people in the US. Like Avedro, SERVImed’s RIBOCROSS holds an FDA orphan drug designation for its proprietary riboflavin formulation for the treatment of keratoconus in patients undergoing cornea cross-linking procedures.

“The combination of SERVImed’s proven RIBOCROSS and TECLens’ proven CXLens® will provide patients with a comfortable, non-invasive alternative to the treatment of ectatic disorders. Unlike any other cross-linking system, CXLens® can treat both eyes simultaneously. Our combination product with RIBOCROSS will significantly increase clinical efficiency and procedure margin for physicians practicing corneal cross- linking”, said TECLens CEO, David Acker.

“We are very excited about this partnership, and strongly convinced that the combination of TECLens’ technology and SERVImed’s expertise will provide patients and physicians with an innovative, more efficient and safer corneal cross-linking procedure, said SERVImed CEO , Francesco Napolitano.

About TECLens (www.TECLens.com)
Based in Stamford, CT, TECLens is a clinical-stage medical device company developing an innovative, non-invasive cornea cross-linking procedure to treat keratoconus, low order myopia and eventually presbyopia. TECLens’ proprietary ‘on- eye’ CXL technology consists of a single-use disposable contact lens (CXLens®) and a small control system, which provide integrated real-time ultrasound feedback and patterned ultraviolet light delivery. TECLens believes on-eye cross-linking will become a safe, simple, and permanent alternative to LASIK, contact lenses, and eyeglasses for millions of people with vision errors.

About SERVImed Industrial Spa
Based in Rome, Italy, SERVImed Industrial is an R&D and manufacturing company, focused on Ophthalmic Medical Devices. SERVImed’s portfolio includes patented solutions and devices for corneal cross-linking, eye drops and diagnostics. SERVImed’s patented cross-linking solutions are based on a unique formulation with riboflavin and vitamin E TPGS. They enhance corneal penetration while protecting the cornea, resulting in effective treatments, even in EPI-ON. SERVImed’s CXL solutions are currently used worldwide in different applications, including its own EPI-ON customized protocol with a 7-year published follow-up (Custom Fast CXL).

Close Menu